Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma

Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):334-336. doi: 10.1016/j.ijrobp.2023.10.045.

Authors

Tyler A Lanman¹, Toni Q Cao², Julie J Miller¹, Seema Nagpal³

Affiliations

¹ Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
² Department of Neurology, Stanford University, Palo Alto, California.
³ Department of Neurology, Stanford University, Palo Alto, California. Electronic address: snagpal@stanford.edu.

PMID: 38220256
DOI: 10.1016/j.ijrobp.2023.10.045

No abstract available

Publication types

Editorial

MeSH terms

Brain Neoplasms* / radiotherapy
Diamines*
Glioma* / radiotherapy
Humans
Indigo Carmine
Isocitrate Dehydrogenase / genetics
Mutation
Pyridines*

Substances

Isocitrate Dehydrogenase
Indigo Carmine
vorasidenib
Diamines
Pyridines